Version 1
: Received: 21 August 2020 / Approved: 22 August 2020 / Online: 22 August 2020 (04:58:03 CEST)
Version 2
: Received: 31 August 2020 / Approved: 31 August 2020 / Online: 31 August 2020 (04:32:48 CEST)
How to cite:
Seliger, B.; Massa, C.; Yang, B.; Bethmann, D.; Kappler, M.; Eckert, A.; Wickenhauser, C. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. Preprints2020, 2020080490. https://doi.org/10.20944/preprints202008.0490.v2
Seliger, B.; Massa, C.; Yang, B.; Bethmann, D.; Kappler, M.; Eckert, A.; Wickenhauser, C. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. Preprints 2020, 2020080490. https://doi.org/10.20944/preprints202008.0490.v2
Seliger, B.; Massa, C.; Yang, B.; Bethmann, D.; Kappler, M.; Eckert, A.; Wickenhauser, C. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. Preprints2020, 2020080490. https://doi.org/10.20944/preprints202008.0490.v2
APA Style
Seliger, B., Massa, C., Yang, B., Bethmann, D., Kappler, M., Eckert, A., & Wickenhauser, C. (2020). Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. Preprints. https://doi.org/10.20944/preprints202008.0490.v2
Chicago/Turabian Style
Seliger, B., Alexander Eckert and Claudia Wickenhauser. 2020 "Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma" Preprints. https://doi.org/10.20944/preprints202008.0490.v2
Abstract
β2-m, β2-microglobulin; CAF, cancer associated fibroblast; CSC, cancer stem cell; CTL, cytotoxic T lymphocyte; DC, dendritic cell; ECM, extracellular matrix; EGF-R, epidermal growth factor receptor; ER, endoplasmic reticulum; FDA, Food and Drug Administration; HLA, human leukocyte antigen; HNSCC, head and neck squamous cell carcinoma; HPV, human papilloma virus; ICP immune checkpoint; ICPi, immune checkpoint inhibitor; IFN, interferon; LMP, low molecular weight protein; mAb, monoclonal antibody; MDSC, myeloid-derived suppressor cell; mTOR, mammalian target of rapamycin; MSI, multispectral imaging; NK, natural killer; OS, overall survival; PBL, peripheral blood lymphocytes; PBMNC, peripheral blood mononuclear cells; PD1, programmed death receptor 1; PD-L1, programmed death ligand 1; PFS, progression-free survival; PI3K, phosphatidyl-linositol-3-kinase; R/M, recurrence and or metastatic; STAT, signal transducer and activator of transcription; TAA, tumor-associated antigen; TAM, tumor associated macrophages; TAP, transporter associated with antigen processing; TCR, T cell receptor; TIL, tumor-infiltrating lymphocyte; TLS, tertiary lymphoid structure; TME, tumor microenvironment; Treg, regulatory T cell; TSA, tumor-specific antigen; VEGF, vascular endothelial growth factor; VEGF-R, vascular endothelial growth factor receptor.
Keywords
head and neck squamous cell carcinoma; immune escape; tumor microenvironment; immune responses; immunotherapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
Commenter: Daniel Bethmann
Commenter's Conflict of Interests: Author